Top 5 Infectious Disease News Stories Week of November 23-30
November 30th 2024This week, GigaGen has launched a Phase 1 trial for GIGA-2339, a potential functional cure for chronic Hepatitis B, public health concerns like the California raw milk recall due to H5N1 and new findings linking lung dysfunction to cognitive decline in Long COVID patients, and more.
New Immunotherapy Approach Targets Immune System to Treat Chronic Hepatitis B
Published: November 29th 2024 | Updated: November 29th 2024This study explores HLA-E as a target to activate the immune system in HBV infection, identifying a stable peptide, Env371-379 L6I, that effectively triggers T-cell responses.
Considering a Beta Lactam as Adjunctive Therapy for Staphylococcus aureus Early in Treatment
November 25th 2024This bacteremia can present heterogeneously and be difficult to contain, especially in an older patient population. Daniel B. Chastain, PharmD, BCIDP, AAHIVP, FIDSA, reviews the data of this class of therapies and how it may be clinically beneficial in combination with other antimicrobials.
Top 5 Infectious Disease News Stories Week of November 16-22
November 23rd 2024Recent studies show oral vancomycin reduces CDI by 64% in stem cell transplant patients, Biktarvy is effective for HIV/HBV co-infection, climate change drives rising dengue cases, and a 7-day antibiotic regimen is as effective as 14 days for bloodstream infections.
One Health, One Mission: Combatting AMR During US Antibiotic Awareness Week 2024
November 22nd 2024Along with the CDC, we highlight the One Health approach and advocate for effective infection control measures, such as vaccination and innovative technologies, to prevent the spread of resistant pathogens and combat AMR.
7-Day Antibiotic Regimen Found Noninferior to 14-Day Treatment for Bloodstream Infections
November 21st 2024The BALANCE trial suggests that shorter treatment durations may reduce healthcare costs, antibiotic exposure, and antimicrobial resistance risk, providing an alternative for critically ill patients.